Members

Oncodrex

Oncodrex’s discovery of unique molecular signatures of metastatic cancers allows the Company to develop targeted therapeutics for those cancers, as well as companion diagnostics to identify patients who will respond to the therapeutics. Combined, this provides a significant differentiator from the current standard of care.

Contact Info

23 Edington Point Winnipeg R3Y 0A2 MB Canada
P: 1 204 416 8256
F: 1 204 416 8256
W: www.vastcon.com

member

Back